BCIQ Profiles

Company Profile Report
0610 ECP Kojin
BioCentury & Getty Images

Emerging Company Profile

Kojin launches to exploit ferroptosis-vulnerable cancer cell state

Emerging Company Profile: Kojin to use Polaris, Newpath, Cathay-led $60M A round to develop ferroptosis-based cancer therapies

Jun 10, 2021 | 8:52 PM GMT

Kojin, which launched Wednesday with a $60 million series A led by Polaris Partners, Newpath Partners and Cathay Health, is pursuing drug development with an approach based on cell state biology, starting with ferroptosis

Read the full 718 word article

How to gain access

Continue reading with a
two-week free trial.